Saar Gill, MD, PhD

Dr. Gill received training in clinical hematology in his native Australia, followed by a postdoctoral fellowship at Stanford University. Since 2011, he has been working on the development of genetically engineered immune cells for cancer treatment. Dr. Gill is a physician-scientist who places strong emphasis on translational research; concepts developed in his laboratory have already led to several clinical trials for the treatment of hematologic malignancies. He specializes in treating patients with leukemia and performing bone marrow transplantation. Furthermore, he has led clinical trials involving CAR-T cells for chronic and acute leukemias.

With a research laboratory focused on the interface between adoptive cellular therapy and genetic engineering, Dr. Gill stands as a foremost innovator in the field of cell and gene therapy. This is evident through his status as one of the most prolific patent inventors globally in the field and his creation of 2 biotherapeutics companies: Carisma Therapeutics, a developer of macrophage-based cellular therapeutics, and Interius BioTherapeutics, which is focused on in vivo delivery of gene therapies. Through his tireless efforts and exceptional achievements, Dr. Gill continues to push the boundaries of scientific knowledge and make significant contributions to the field of cancer treatment.